糖尿病、代谢合并症与肝细胞癌风险:两项前瞻性队列研究结果
基于护士健康研究(NHS)120,826名女性和卫生专业人员随访研究(HPFS)50,284名男性,随访32年共记录112例肝细胞癌(HCC)。2型糖尿病(T2D)与HCC风险升高独立相关(多变量HR 4.59,95%CI 2.98-7.07),且随糖尿病病程延长和代谢合并症数量增加而进一步升高。
要点
- 2型糖尿病与HCC风险升高独立相关,多变量HR为4.59(95%CI 2.98-7.07)。
- 糖尿病病程越长HCC风险越高,≥10年者多变量HR达7.52(95%CI 3.88-14.58)。
- 合并4项代谢合并症者HCC风险为无代谢合并症者的8.1倍(95%CI 2.48-26.7)。
核心结论
- 在两项美国男女性前瞻性队列中,2型糖尿病与肝细胞癌风险升高独立相关,且该风险随糖尿病病程延长和代谢合并症增多而增强,提示胰岛素抵抗在HCC发病机制中的重要性。
研究设计与样本
- 护士健康研究(NHS)1980年纳入120,826名女性,卫生专业人员随访研究(HPFS)1986年纳入50,284名男性,随访至2012年。
- 医师诊断的2型糖尿病在基线确认并每两年更新,采用Cox比例风险回归计算年龄和多变量校正的HR及95%CI。
主要发现
- 随访32年(4,488,410人年)共记录112例HCC(女性69例,男性43例)。
- 2型糖尿病与HCC风险升高相关(多变量HR 4.59,95%CI 2.98-7.07),且随糖尿病病程延长风险升高(Ptrend<0.001)。
- 与非糖尿病者相比,糖尿病病程0-<2年者多变量HR 2.96(95%CI 1.57-5.60),2-<10年者HR 6.08(95%CI 2.96-12.50),≥10年者HR 7.52(95%CI 3.88-14.58)。
- 代谢合并症(2型糖尿病、肥胖、高血压、血脂异常)数量增加与HCC风险升高相关(Ptrend<0.001),合并4项者较无代谢合并症者HCC风险升高8.1倍(95%CI 2.48-26.7)。
- 在2型糖尿病患者中,胰岛素使用(HR 2.04,95%CI 0.69-6.09)和口服降糖药使用(HR 1.45,95%CI 0.69-3.07)与HCC风险均无显著关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk. From the Nurses' Health Study (NHS), 120,826 women were enrolled in 1980, and from the Health Professionals Follow-up Study (HPFS), 50,284 men were enrolled in 1986 and followed through 2012. Physician-diagnosed T2D was ascertained at baseline and updated biennially. Cox proportional hazards regression models were used to calculate age- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident HCC. Over 32 years of follow-up (4,488,410 person-years), we documented 112 cases of HCC (69 women, 43 men). T2D was associated with an increased HCC risk (multivariable HR, 4.59; 95% CI, 2.98-7.07), as was an increasing T2D duration (Ptrend < 0.001). Compared to nondiabetics, the multivariable HRs for HCC were 2.96 (95% CI, 1.57-5.60) for 0-<2 years; 6.08 (95% CI, 2.96-12.50) for 2-<10 years; and 7.52 (95% CI, 3.88-14.58) for ≥10 years. Increasing number of metabolic comorbidities (T2D, obesity, hypertension, and dyslipidemia) was associated with increased HCC risk (Ptrend < 0.001); compared to individuals without metabolic comorbidity, those with four metabolic comorbidities had an 8.1-fold increased HCC risk (95% CI, 2.48-26.7). In T2D, neither insulin use nor oral hypoglycemic use was significantly associated with HCC risk (HR, 2.04 [95% CI, 0.69-6.09] and HR, 1.45 [95% CI, 0.69-3.07], respectively). CONCLUSION: T2D is independently associated with increased risk for HCC in two prospective cohorts of U.S. men and women. This risk is enhanced with prolonged diabetes duration and with comorbid metabolic conditions, suggesting the importance of insulin resistance in the pathogenesis of HCC. (Hepatology 2018;67:1797-1806).
引用
- Simon TG, King LY, Chong DQ, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology. 2018. PMID: 29152763. doi:10.1002/hep.29660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。